ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Confirmation of the Feasibility of Ex Vivo Creation of a Novel Human Multi-Chimeric Cells Therapy for Tolerance Induction in Vascularized Composite Allotransplantation

J. Cwykiel, G. Rafidi, M. Siemionow.

Orthopaedics, University of Illinois at Chicago, Chicago, IL.

Meeting: 2018 American Transplant Congress

Abstract number: 505

Keywords: Stem cells, Tolerance

Session Information

Date: Tuesday, June 5, 2018

Session Name: Concurrent Session: Cellular Therapies and to Promote Tolerance

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:18pm-5:30pm

Location: Room 606/607

Related Abstracts
  • Human Hematopoietic Chimeric Cells as a Novel Approach for Tolerance Induction After Transplantation
  • Confirmation of the Safety of Cryopreserved Human Cord Blood Derived Di-Chimeric Cells in the NSG Mouse Model.

Purpose:Various stem cell-based therapies have been proposed as supportive treatments for patients following solid organ and vascularized composite allotransplantation (VCA) to achieve donor-specific tolerance and eliminate the toxic, systemic, life-long, multi-drug immunosuppression. We introduce a novel cellular therapy of ex vivo created umbilical cord blood derived multi-chimeric cells (mCC) as an alternative approach to bone marrow based therapies in support of VCA. The aim of this study was to establish the ex vivo fusion protocol and characterize in vitro the phenotype, genotype, viability and proliferative potential of fused human mCC.

Methods: Twenty-two ex vivo fusions of human umbilical cord blood (UCB) cells were performed. Mononuclear cells (MNC) were isolated from UCB originating from three unrelated donors. Next, MNC were stained separately by PKH26, PKH67 and eFluor670 proliferation dye and fused using polyethylene glycol (PEG). Triple PKH26/PKH67/eFluor670 stained mCC were sorted and assessed by confocal microscopy and flow cytometry for the efficacy of the cell fusion procedure. The viability of mCC (Trypan blue and LIVE/DEAD cell viability assay) and distribution of hematopoietic surface markers (CD4, CD8, CD19, CD45 and CD90) were performed by flow cytometry. PCR-rSSOP (Antigens: A, B, C, Bw, DRB1, DQB1, DR51, DR52 and DR53), and STR-PCR (Loci: TH01, D21S11, D5S818, D13S317, D7S820, D16S539, vWA, TPOX) characterized the genotype of mCC. Proliferative potential of mCC was assessed by colony forming unit (CFU) assay.

Results: Flow cytometry and confocal microscopy analysis confirmed UCB fusion and creation of human mCC. Using PCR-rSSOP and STR-PCR assays, we determined that human mCC are sharing HLA class I and class II antigens, as well as selected loci specific for all three UCB donors used for fusion. After fusion 90-95% of cells were viable. Phenotype characterization showed similar percentage and pattern of hematopoietic markers distribution on the surface of mCC and UCB donors. Maintenance of proliferative properties of mCC was confirmed by CFU assay.

Conclusions: We have successfully confirmed the feasibility of ex vivo fusion procedure and creation of human mCC. We characterized the phenotype, genotype, viability and proliferative potential of mCC. This unique concept of mCC introduces a novel universal therapy for tolerance induction in solid organ and VCA transplantation.

CITATION INFORMATION: Cwykiel J., Rafidi G., Siemionow M. Confirmation of the Feasibility of Ex Vivo Creation of a Novel Human Multi-Chimeric Cells Therapy for Tolerance Induction in Vascularized Composite Allotransplantation Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Cwykiel J, Rafidi G, Siemionow M. Confirmation of the Feasibility of Ex Vivo Creation of a Novel Human Multi-Chimeric Cells Therapy for Tolerance Induction in Vascularized Composite Allotransplantation [abstract]. https://atcmeetingabstracts.com/abstract/confirmation-of-the-feasibility-of-ex-vivo-creation-of-a-novel-human-multi-chimeric-cells-therapy-for-tolerance-induction-in-vascularized-composite-allotransplantation/. Accessed January 26, 2021.

« Back to 2018 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.